about
Hyaluronic acid-coated chitosan nanoparticles induce ROS-mediated tumor cell apoptosis and enhance antitumor efficiency by targeted drug delivery via CD44Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells.Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicineAptamers as theranostic agents: modifications, serum stability and functionalisationInflammation and cancer stem cells.Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis.Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles.Fabrication of high specificity hollow mesoporous silica nanoparticles assisted by Eudragit for targeted drug delivery.RNA aptamers targeting cancer stem cell marker CD133.Chitosan nanoparticles loaded hydrogels promote skin wound healing through the modulation of reactive oxygen species.Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery.Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody.Systematic Screening of Commonly Used Commercial Transfection Reagents towards Efficient Transfection of Single-Stranded OligonucleotidesThree decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer developmentThe control of epidermal growth factor grafted on mesoporous silica nanoparticles for targeted deliveryA Detailed Protein-SELEX Protocol Allowing Visual Assessments of Individual Steps for a High Success Rate
P50
Q28566589-8A0264AD-FC47-425B-A25D-332470023830Q33919094-5C0650FB-2A2E-4411-8FEE-F3348608895CQ34698624-CBDD6293-E81C-4F74-B207-4BE957BDB6A3Q37383122-B44F4286-8B1B-48B3-BE8D-F946920340D2Q38128635-C74E2B13-A4FC-4AD5-8594-751A33E451C3Q38825657-C2A67516-66F9-4CBC-9F59-FEE2657F6EB2Q38846339-2F8FB374-7D9B-42DA-B1A1-B7122D8899A3Q38916896-531FB9AC-FC1C-4BCE-99DC-AD6DA8FC03A7Q39235728-89995FF3-17B3-4815-B034-8231BD5914AAQ46242312-1CB322FC-BE32-4EDA-82A0-AC9C0B55F789Q47108689-965DFAB8-F11E-491A-B703-54160D7C12F8Q53215165-711181F0-4855-4108-8B53-116FEE3B01BAQ57295326-CBC88473-075B-4F4E-8FF8-EF999D613B22Q58609444-D3CE35D0-BBE2-40EB-B955-E219B4428517Q63500824-B200ABED-8C0B-448F-8428-96767BA3A3E3Q91281711-545B0986-2F99-4538-AE49-E24F5BA0765C
P50
description
researcher ORCID 0000-0002-9623-8800
@en
name
Tao Wang
@ast
Tao Wang
@en
Tao Wang
@es
Tao Wang
@nl
type
label
Tao Wang
@ast
Tao Wang
@en
Tao Wang
@es
Tao Wang
@nl
prefLabel
Tao Wang
@ast
Tao Wang
@en
Tao Wang
@es
Tao Wang
@nl
P106
P1153
57206718979
P2456
12/5838-43
P31
P496
0000-0002-9623-8800